Pankaj Gupta, MBBS, MD, FACP - VA Long ...

Dr. Pankaj Gupta

Claim this profile

Tibor Rubin VA Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
30 drugs studied

Area of expertise

1Lung Cancer
Pankaj Gupta has run 6 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage III
2Non-Small Cell Lung Cancer
Pankaj Gupta has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage III

Affiliated Hospitals

Image of trial facility.
Tibor Rubin VA Medical Center
Image of trial facility.
V.A. Long Beach Healthcare System

Clinical Trials Pankaj Gupta is currently running

Image of trial facility.

Carboplatin + Cabazitaxel

for Prostate Cancer

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.
Recruiting2 awards Phase 35 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Pankaj Gupta

Clinical Trial Related6 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Pankaj Gupta has experience with
  • Biospecimen Collection
  • Carboplatin
  • Pembrolizumab
  • Pemetrexed Disodium
  • Gemcitabine Hydrochloride
  • Prophylactic Cranial Irradiation

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Pankaj Gupta specialize in?
Is Pankaj Gupta currently recruiting for clinical trials?
Are there any treatments that Pankaj Gupta has studied deeply?
What is the best way to schedule an appointment with Pankaj Gupta?
What is the office address of Pankaj Gupta?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security